13 Papers
1 Citations
Meisi Yan is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Meisi Yan include Harbin Medical University.
Chat about Author
Papers
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Ri Yao Yang,Linlin Sun,Linlin Sun,Ching Fei Li,Yu Han Wang,Yu Han Wang,Jun Yao,Hui Li,Hui Li,Meisi Yan,Meisi Yan,Wei Chao Chang,Jung Mao Hsu,Jung Mao Hsu,Jong Ho Cha,Jong Ho Cha,Jennifer L. Hsu,Cheng Wei Chou,Cheng Wei Chou,Xian Sun,Xian Sun,Yalan Deng,Chao Kai Chou,Dihua Yu,Mien Chie Hung,Mien Chie Hung +25 more
TL;DR: This paper showed that anti-Galectin-9 therapy selectively expands intratumoral TIM-3+ cytotoxic CD8 T cells and immunosuppressive regulatory T cells (Treg cells) and suggests Gal-9 as a promising target for immunotherapy.
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng Huan Lee,Ying Nai Wang,Wei Ya Xia,Chia-Hung Chen,Kun Ming Rau,Leiguang Ye,Yongkun Wei,Chao Kai Chou,Shao Chun Wang,Meisi Yan,Meisi Yan,Chih Yen Tu,Te Chun Hsia,Shu Fen Chiang,K. S. Clifford Chao,Ignacio I. Wistuba,Jennifer L. Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Gabriel N. Hortobagyi,Mien Chie Hung +20 more
TL;DR: A method to resolve this by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process termed sample deglycosylation, significantly improves anti-PD-L1 antibody binding affinity and signal intensity, resulting in more accurate PD-L 1 quantification and prediction of clinical outcome.
322
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Zhou Jiang,Seung Oe Lim,Seung Oe Lim,Meisi Yan,Meisi Yan,Jennifer L. Hsu,Jun Yao,Yongkun Wei,Shih Shin Chang,Hirohito Yamaguchi,Hirohito Yamaguchi,Heng Huan Lee,Baozhen Ke,Jung Mao Hsu,Jung Mao Hsu,Li Chuan Chan,Gabriel N. Hortobagyi,Liuqing Yang,Chunru Lin,Dihua Yu,Mien Chie Hung +20 more
TL;DR: In this paper, the authors showed that tumors with high tyro3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-(1)/PD-(L1)/L1 therapy.
Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function
Ke Wu,Meisi Yan,Tong-Xin Liu,Zheng-Hua Wang,Yu-Qiu Duan,Yan Xia,Guimei Ji,Yuling Shen,Lei Wang,Lin Li,Peixiang Zheng,Bofei Dong,Qingang Wu,Liwei Xiao,Xueying Yang,Hao-Miao Shen,Jingjing Zhang,Jinfeng Yi,Yu-Yi Deng,Xu Qian,Leina Ma,Jing Fang,Qingxin Zhou,Zhimin Lu,Daqian Xu +24 more
TL;DR: Findings reveal a critical mechanism by which tumour cells counteract ferroptosis by non-metabolic function of C KB-enhanced GPX4 stability and underscore the potential to target the protein kinase activity of CKB for cancer treatment.
75
Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients
TL;DR: The microenvironment of lymph node metastasized tumors (LNMT) determines tumor progression and response to therapy, but a systematic study of LNMT is lacking as mentioned in this paper .